Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;11(6):418-422.
doi: 10.1159/000452194. Epub 2016 Nov 15.

Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer

Soumaya Labidi  1 , Nesrine Mejri  1 , Aymen Lagha  1 , Nouha Daoud  1 , Houda El Benna  1 , Mehdi Afrit  1 , Hamouda Boussen  1
Affiliations
Review

Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer

Soumaya Labidi et al. Breast Care (Basel). 2016 Dec.

Abstract

Human epidermal growth factor receptor-2 (HER2) is amplified in 25-30% of breast cancers and is associated with aggressive disease and poorer survival. Multiple anti-HER2 targeted therapies have dramatically changed management and outcome of this subgroup, both in adjuvant and metastatic settings. Despite the improvement of survival thanks to trastuzumab, unclear mechanisms of resistance occur, which has led to the development of new anti-HER2 therapies such as lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1). The optimal sequence of the available drugs is still not well established. All this progress raises the question of toxicity that need to be managed, especially with longer survival of patients. In this article, we review different anti-HER2 therapies used in HER2-positive m etastatic breast cancer.

Keywords: HER2; Metastatic breast cancer; Targeted therapy.

PubMed Disclaimer

References

    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403. - PubMed
    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Wolff A, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: AmericanSociety of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31:3997–4013. - PubMed
    1. Slamon D, Clark G, Wong S, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science. 1987;235:177–182. - PubMed
    1. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. - PubMed